telaprevir: Clinical Trials

25 trials of telaprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 5 terminated, 1 unknown, 1 withdrawn. 25 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 225Completed 18, Terminated 5, Unknown 1, Withdrawn 1
Phase 11Terminated 1
Phase 31Withdrawn 1

Follow telaprevir: new trials by email Literature Review of telaprevir trials Research Report on telaprevir

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
Telaprevir and Sofosbuvir - Hepatitis C, Chronic
Phase 2CompletedUniversity of Florida202013-12-012018-04-23
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
Telaprevir, Peginterferon alfa-2a, Ribavirin - Hepatitis C
Phase 2 / Phase 3WithdrawnTimothy Morgan, MD2013-08-012014-05-14
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
Miravirsen, Telaprevir, Ribavirin - Hepatitis C, Chronic
Phase 2UnknownSantaris Pharma A/S202013-06-012014-11-18
Interaction Between Paroxetine and Telaprevir
Paroxetine, telaprevir - Hepatitis C Infection, Depression
Phase 2TerminatedRadboud University Medical Center32013-05-012020-12-08
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C
Phase 1 / Phase 2TerminatedVertex Pharmaceuticals Incorporated422013-01-012016-07-20
Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection
Phase 2TerminatedMassBiologics112012-11-212021-02-05
Dose Ranging of GSK2336805 in Combination Therapy
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a - Hepatitis C, Chronic
Phase 2CompletedGlaxoSmithKline2862012-08-012017-06-02
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus
Phase 2CompletedVertex Pharmaceuticals Incorporated642012-07-012014-07-04
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus
Phase 2CompletedVertex Pharmaceuticals Incorporated1032012-02-012014-10-20
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a - Hepatitis C
Phase 2TerminatedVertex Pharmaceuticals Incorporated612012-02-012015-06-18
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
Ribavirin, Mericitabine, Peginterferon Alfa-2a - Hepatitis C
Phase 2CompletedHoffmann-La Roche802011-11-302017-04-24
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Avatrombopag, Placebo, Pegylated interferon (PEG-IFN) - Thrombocytopenia
Phase 2CompletedEisai Inc.652011-11-012018-02-22
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
Telaprevir, pegIFN alfa-2a, Ribavirin - Hepatitis C, Chronic, HIV Infection
Phase 2CompletedANRS, Emerging Infectious Diseases702011-04-012026-04-02
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection
Phase 2TerminatedVertex Pharmaceuticals Incorporated1522010-08-012020-09-30
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose) - Hepatitis C, HIV Infections
Phase 2CompletedVertex Pharmaceuticals Incorporated622009-10-012013-10-10
Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Telaprevir, Peginterferon alfa-2a, Ribavirin - Hepatitis C
Phase 2CompletedWeill Medical College of Cornell University152009-05-012015-03-20
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
Telaprevir, Pegylated-interferon-alfa-2a, Placebo - Hepatitis C
Phase 2CompletedTibotec BVBA242008-01-012013-09-09
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
MP-424 (Telaprevir) - Hepatitis C
Phase 2CompletedTanabe Pharma Corporation152008-01-012026-01-06
A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
Telaprevir, Peg-IFN-alfa-2a + Ribavirin (Standard Treatment), Placebo - Hepatitis C, Chronic
Phase 2CompletedTibotec BVBA522007-12-012013-06-17
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
Telaprevir, Ribavirin, Pegylated interferon alfa 2a - Hepatitis C
Phase 2CompletedVertex Pharmaceuticals Incorporated1172007-10-012014-08-05

Showing 20 of 25. Sign in to see all of them.

Conditions studied

Hepatitis C (14)  ·  Hepatitis C, Chronic (11)  ·  HIV Infections (2)  ·  Depression (1)  ·  Infections (1)  ·  Thrombocytopenia (1)

Sponsors

Vertex Pharmaceuticals Incorporated (11)  ·  Tibotec BVBA (3)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Eisai Inc. (1)  ·  GlaxoSmithKline (1)  ·  Hoffmann-La Roche (1)  ·  MassBiologics (1)  ·  Radboud University Medical Center (1)  ·  Santaris Pharma A/S (1)  ·  Tanabe Pharma Corporation (1)  ·  Timothy Morgan, MD (1)  ·  University of Florida (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (17)  ·  Germany (9)  ·  France (8)  ·  Puerto Rico (6)  ·  United Kingdom (6)  ·  Canada (5)  ·  Netherlands (4)  ·  Spain (4)  ·  Austria (3)  ·  Belgium (3)  ·  Italy (2)  ·  Bulgaria (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Poland (1)

Top investigators

Alireza Manhuchehri (1)  ·  Andrew H. Talal, MD, MPH (1)  ·  David Burger, PharmD, PhD (1)  ·  Fumitaka Suzuki, MD (1)  ·  Michael Hodges, MD (1)  ·  Nathalie Adda, MD (1)  ·  Timothy R Morgan, MD (1)

Results publications

PMID 19403902, PMID 19403903, PMID 20375406, PMID 21690488, PMID 22387529, PMID 23383655, PMID 23685940, PMID 24811404, PMID 24886541, PMID 24901821, PMID 24982088, PMID 25139963, PMID 25512630, PMID 26752189